Join the Dermatitis group to help and get support from people like you.
Dermatitis News
Global Burden of Atopic Dermatitis in Older Adults Is Considerable
WEDNESDAY, May 7, 2025 – The global burden of atopic dermatitis (AD) in older adults is considerable and is expected to continue increasing to 2050, according to a study published online April 1 in...
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
FRIDAY, March 14, 2025 – Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment,...
Study IDs Signs of Topical Steroid Withdrawal in Atopic Dermatitis
WEDNESDAY, Jan. 22, 2025 – Self-reported manifestations of topical steroid withdrawal (TSW) in atopic dermatitis (AD) include erythema, desquamation, dryness, and oozing affecting the face, neck,...
FDA Medwatch Alert: Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health
October 30, 2024 – FDA is warning consumers to not purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids. This product, sold by Chemigroup France, formerly...
Are 'Elimination Diets' Much Help Against Child Eczema?
FRIDAY, Oct. 25, 2024 – Cutting certain foods from a child’s diet isn’t likely to improve their eczema symptoms, a new study finds. Eczema, also known as atopic dermatitis, results from an ove...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 – The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis....
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
FRIDAY, Aug. 30, 2024 – Dietary intake of vitamin E may potentially lower the risk for atopic dermatitis, according to a study published online Aug. 9 in Skin Research & Technology. Siqing Wang, ...
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
MONDAY, Aug. 12, 2024 – For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients, according to a...
Antihypertensives Linked to Eczematous Dermatitis in Seniors
FRIDAY, May 24, 2024 – Antihypertensive drugs are associated with an increased risk for eczematous dermatitis in older adults, and the effect sizes are largest for diuretics and calcium channel...
FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis
MADISON, N.J.--(BUSINESS WIRE) December 28, 2021 --LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab-ldrm) for the treatment of m...
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
TARRYTOWN, N.Y. and PARIS, May 26, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupi...
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with...
FDA Approves Dupixent (dupilumab) for Eczema
March 28, 2017 – The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for...
FDA Approves Eucrisa (crisaborole) for Eczema
December 14, 2016 – The U.S. Food and Drug Administration today approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older....
Taro Receives FDA Approval For Topicort (desoximetasone) Topical Spray, 0.25%
HAWTHORNE, N.Y.--April 12, 2013--Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application (“N...
Further information
Related condition support groups
Eczema, Contact Dermatitis, Atopic Dermatitis, Poison Ivy, Dermatological Disorders
Related drug support groups
triamcinolone, clobetasol, fluocinonide, prednisolone, desonide, halobetasol, Therapeutic